Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Indian Journal of Pediatrics
Published in: Indian Journal of Pediatrics 5/2019

01-05-2019 | Isoniazid | Review Article

Pharmacokinetics of First-Line Anti-Tubercular Drugs

Authors: Aparna Mukherjee, Rakesh Lodha, S. K. Kabra

Published in: Indian Journal of Pediatrics | Issue 5/2019

Login to get access

Abstract

Determining the optimal dosages of isoniazid, rifampicin, pyrazinamide and ethambutol in children is necessary to obtain therapeutic serum concentrations of these drugs. Revised dosages have improved the exposure of 1st line anti-tubercular drugs to some extent; there is still scope for modification of the dosages to achieve exposures which can lead to favourable outcome of the disease. High dose of rifampicin is being investigated in clinical trials in adults with some benefit; studies are required in children. Inter-individual pharmacokinetic variability and the effect of age, nutritional status, Human immunodeficiency virus (HIV) infection, acetylator genotype may need to be accounted for in striving for the dosages best suited for an individual.
Literature
1.
McCarver DG. Applicability of the principles of developmental pharmacology to the study of environmental toxicants. Pediatrics. 2004;113:969–72.PubMed
2.
Pariente-Khayat A, Rey E, Gendrel D, et al. Isoniazid acetylation metabolic ratio during maturation in children. Clin Pharmacol Ther. 1997;62:377–83.
3.
Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs. 2002;62:2169–83.CrossRefPubMed
4.
Brunton LL, Chabner BA, Knollmann BC. Goodman & Gilman’s the pharmacological basis of therapeutics. 12th ed. US: McGraw-Hill Medical; 2011.
5.
Debré R. Systematic treatment of primary tuberculosis. Am Rev Tuberc. 1956;74:191–6.PubMed
6.
Seth V, Beotra A, Seth SD, et al. Serum concentrations of rifampicin and isoniazid in tuberculosis. Indian Pediatr. 1993;30:1091–8.
7.
Lanier VS, Russel WF Jr, Heaton A, Robinson A. Concentrations of active isoniazid in serum and cerebrospinal fluid of patients with tuberculosis treated with isoniazid. Pediatrics. 1958;21:910–5.PubMed
8.
Akbani Y, Bolme P, Lindblad BS, Rahimtoola RJ. Control of streptomycin and isoniazid in malnourished children treated for tuberculosis. Acta Paediatr Scand. 1977;66:237–40.CrossRefPubMed
9.
Seth V, Beotra A, Senwal OP, Mukhopadhyaya S. Monitoring of serum rifampicin and isoniazid levels in childhood tuberculosis. Am Rev Respir Dis. 1990;141:A337.
10.
Seth V, Beotra A, Bagga A, Seth S. Drug therapy in malnutrition. Indian Pediatr. 1992;29:1341–6.PubMed
11.
Seth V, Seth SD, Beotra A, Semwal OP, D’monty V, Mukhopadhya S. Isoniazid and acetylisoniazid kinetics in serum and urine in pulmonary primary complex with intermittent regimen. Indian Pediatr. 1994;31:279–85.PubMed
12.
Roy V, Tekur U, Chopra K. Pharmacokinetics of isoniazid in pulmonary tuberculosis--a comparative study at two dose levels. Indian Pediatr. 1996;33:287–91.PubMed
13.
Donald PR, Gent WL, Seifart HI, Lamprecht JH, Parkin DP. Cerebrospinal fluid isoniazid concentrations in children with tuberculous meningitis: the influence of dosage and acetylation status. Pediatrics. 1992;89:247–50.PubMed
14.
Rey E, Gendrel D, Treluyer JM, et al. Isoniazid pharmacokinetics in children according to acetylator phenotype. Fundam Clin Pharmacol. 2001;15:355–9.
15.
Schaaf HS, Parkin DP, Seifart HI, et al. Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Arch Dis Child. 2005;90:614–8.
16.
McIlleron H, Willemse M, Werely CJ, et al. Isoniazid plasma concentrations in a cohort of south African children with tuberculosis: implications for international pediatric dosing guidelines. Clin Infect Dis. 2009;48:1547–53.
17.
Thee S, Detjen AA, Wahn U, Magdorf K. Isoniazid pharmacokinetic studies of the 1960s: considering a higher isoniazid dose in childhood tuberculosis. Scand J Infect Dis. 2010;42:294–8.CrossRefPubMed
18.
Thee S, Seddon JA, Donald PR, et al. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. Antimicrob Agents Chemother. 2011;55:5560–7.
19.
Verhagen LM, López D, Hermans PWM, et al. Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations. Tropical Med Int Health. 2012;17:1449–56.
20.
Ramachandran G, Hemanth Kumar AK, Bhavani PK, et al. Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children. Int J Tuberc Lung Dis. 2013;17:800–6.
21.
Ibrahim M, Engidawork E, Yimer G, Bobosha K, Aseffa A. Pharmacokinetics of isoniazid in Ethiopian children with tuberculosis in relation to the N-acetyltransferase 2 (NAT2) genotype. Afr J Pharm Pharmacol. 2013;7:1124–30.CrossRef
22.
Mukherjee A, Velpandian T, Singla M, Kanhiya K, Kabra SK, Lodha R. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children. BMC Infect Dis. 2015;15:126.CrossRefPubMedPubMedCentral
23.
Jamis-Dow CA, Katki AG, Collins JM, Klecker RW. Rifampin and rifabutin and their metabolism by human liver esterases. Xenobiotica. 1997;27:1015–24.CrossRefPubMed
24.
Chen J, Raymond K. Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. Ann Clin Microbiol Antimicrob. 2006;5:3.CrossRefPubMedPubMedCentral
25.
Ellard GA, Fourie PB. Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption. Int J Tuberc Lung Dis. 1999;3:S301–8; discussion S317–21.
26.
Acocella G, Buniva G, Flauto U. Absorption and elimination of the antibiotic rifampicin in newborns and children. Proceedings of the sixth International Congress of Chemotherapy. Tokyo: Univ Tokyo Press; 1970. p. 755–60.
27.
Schaaf HS, Willemse M, Cilliers K, et al. Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis. BMC Med. 2009;7:19.
28.
Hussels H, Kroening U, Magdorf K. Ethambutol and rifampicin serum levels in children: second report on the combined administration of ethambutol and rifampicin. Pneumonologie. 1973;149:31–8.CrossRefPubMed
29.
McCracken GH Jr, Ginsburg CM, Zweighaft TC, Clahsen J. Pharmacokinetics of rifampin in infants and children: relevance to prophylaxis against Haemophilus influenzae type b disease. Pediatrics. 1980;66:17–21.PubMed
30.
Tan TQ, Mason EO Jr, Ou CN, Kaplan SL. Use of intravenous rifampin in neonates with persistent staphylococcal bacteremia. Antimicrob Agents Chemother. 1993;37:2401–6.CrossRefPubMedPubMedCentral
31.
Mahajan M, Rohatgi D, Talwar V, Patni SK, Mahajan P, Agarwal DS. Serum and cerebrospinal fluid concentrations of rifampicin at two dose levels in children with tuberculous meningitis. J Commun Dis. 1997;29:269–74.PubMed
32.
Thee S, Detjen A, Wahn U, Magdorf K. Rifampicin serum levels in childhood tuberculosis. Int J Tuberc Lung Dis. 2009;13:1106–11.PubMed
33.
Graham SM, Bell DJ, Nyirongo S, Hartkoorn R, Ward SA, Molyneux EM. Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection. Antimicrob Agents Chemother. 2006;50:407–13.CrossRefPubMedPubMedCentral
34.
Roy V, Tekur U, Chopra K. Pharmacokinetics of pyrazinamide in children suffering from pulmonary tuberculosis. Int J Tuberc Lung Dis. 1999;3:133–7.PubMed
35.
Zhu M, Starke JR, Burman WJ, et al. Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis. Pharmacotherapy. 2002;22:686–95.
36.
Gupta P, Roy V, Sethi GR, Mishra TK. Pyrazinamide blood concentrations in children suffering from tuberculosis: a comparative study at two doses. Br J Clin Pharmacol. 2008;65:423–7.CrossRefPubMed
37.
Thee S, Detjen A, Wahn U, Magdorf K. Pyrazinamide serum levels in childhood tuberculosis. Int J Tuberc Lung Dis. 2008;12:1099–101.PubMed
38.
Arya DS, Ojha SK, Semwal OP, Nandave M. Pharmacokinetics of pyrazinamide in children with primary progressive disease of lungs. Indian J Med Res. 2008;128:611–5.PubMed
39.
Roy V, Sahni P, Gupta P, Sethi GR, Khanna A. Blood levels of pyrazinamide in children at doses administered under the revised National Tuberculosis Control Program. Indian Pediatr. 2012;49:721–5.CrossRefPubMed
40.
Thee S, Detjen A, Quarcoo D, Wahn U, Magdorf K. Ethambutol in paediatric tuberculosis: aspects of ethambutol serum concentration, efficacy and toxicity in children. Int J Tuberc Lung Dis. 2007;11:965–71.PubMed
41.
Zhu M, Burman WJ, Starke JR, et al. Pharmacokinetics of ethambutol in children and adults with tuberculosis. Int J Tuberc Lung Dis. 2004;8:1360–7.
42.
Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children. Geneva: World Health Organization; 2015.
43.
World Health Organization. RAPID ADVICE Treatment of tuberculosis in children. Geneva, Switzerland: WHO, Geneva, Switzerland; 2010.
44.
World Health Organization. Guidance for National Tuberculosis Programmes on the management of tuberculosis in children. Geneva, Switzerland: World Health Organization; 2006.
45.
Kiser JJ, Zhu R, DʼArgenio DZ, et al. Isoniazid pharmacokinetics, pharmacodynamics, and dosing in south African infants. Ther Drug Monit. 2012;34:446–51.
46.
Yang H, Enimil A, Gillani FS, et al. Evaluation of the adequacy of the 2010 revised World Health Organization recommended dosages of the first-line antituberculosis drugs for children: adequacy of revised dosages of TB drugs for children. Pediatr Infect Dis J. 2018;37:43–51.
47.
48.
de Steenwinkel JEM, Aarnoutse RE, de Knegt GJ, et al. Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model. Am J Respir Crit Care Med. 2013;187:1127–34.
49.
Horita Y, Alsultan A, Kwara A, et al. Evaluation of the adequacy of WHO revised dosages of the first-line antituberculosis drugs in children with tuberculosis using population pharmacokinetic modeling and simulations. Antimicrob Agents Chemother. 2018;62:pii:e00008–18.
50.
Srivastava S, Deshpande D, Magombedze G, Gumbo T. Efficacy versus hepatotoxicity of high-dose rifampin, pyrazinamide, and moxifloxacin to shorten tuberculosis therapy duration: there is still fight in the old warriors yet! Clin Infect Dis. 2018;67:S359–64.CrossRefPubMed
51.
Boeree MJ, Heinrich N, Aarnoutse R, et al. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis. 2017;17:39–49.
52.
Velásquez GE, Brooks MB, Coit JM, et al. Efficacy and safety of high-dose rifampin in pulmonary tuberculosis. A randomized controlled trial. Am J Respir Crit Care Med. 2018;198:657–66.
53.
Svensson EM, Svensson RJ, Te Brake LHM, et al. The potential for treatment shortening with higher rifampicin doses: relating drug exposure to treatment response in patients with pulmonary tuberculosis. Clin Infect Dis. 2018;67:34–41.CrossRefPubMedPubMedCentral
54.
Hiruy H, Rogers Z, Mbowane C, et al. Subtherapeutic concentrations of first-line anti-TB drugs in south African children treated according to current guidelines: the PHATISA study. J Antimicrob Chemother. 2015;70:1115–23.
55.
Dayal R, Singh Y, Agarwal D, et al. Pharmacokinetic study of isoniazid and pyrazinamide in children: impact of age and nutritional status. Arch Dis Child. 2018;103:1150–4.
56.
Mlotha R, Waterhouse D, Dzinjalamala F, et al. Pharmacokinetics of anti-TB drugs in Malawian children: reconsidering the role of ethambutol. J Antimicrob Chemother. 2015;70:1798–803.
57.
Ramachandran G, Kumar AKH, Kannan T, et al. Low serum concentrations of rifampicin and pyrazinamide associated with poor treatment outcomes in children with tuberculosis related to HIV status. Pediatr Infect Dis J. 2016;35:530–4.
58.
Pouplin T, Bang ND, Toi PV, et al. Naïve-pooled pharmacokinetic analysis of pyrazinamide, isoniazid and rifampicin in plasma and cerebrospinal fluid of Vietnamese children with tuberculous meningitis. BMC Infect Dis. 2016;16:144.
59.
Jeena PM, Bishai WR, Pasipanodya JG, Gumbo T. In silico children and the glass mouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis. Antimicrob Agents Chemother. 2011;55:539–45.CrossRefPubMed
60.
Schaaf HS, Parkin DP, Seifart HI, et al. Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Arch Dis Child. 2005;90:614–8.
61.
Mehta S. Drug disposition in children with protein energy malnutrition. J Pediatr Gastroenterol Nutr. 1983;2:407–17.CrossRefPubMed
62.
Oshikoya KA, Senbanjo IO. Pathophysiological changes that affect drug disposition in protein-energy malnourished children. Nutr Metab. 2009;6:50.
63.
Oshikoya KA, Sammons HM, Choonara I. A systematic review of pharmacokinetics studies in children with protein-energy malnutrition. Eur J Clin Pharmacol. 2010;66:1025–35.CrossRefPubMed
64.
Eriksson M, Bolme P, Habte D, Paalzow L. INH and streptomycin in Ethiopian children with tuberculosis and different nutritional status. Acta Paediatr Scand. 1988;77:890–4.CrossRefPubMed
65.
World Health Organization. Global tuberculosis control - surveillance, planning, financing. Geneva, Switzerland: WHO; 2008.
66.
McIlleron H, Willemse M, Schaaf HS, Smith PJ, Donald PR. Pyrazinamide plasma concentrations in young children with tuberculosis. Pediatr Infect Dis J. 2011;30:262–5.CrossRefPubMed
67.
68.
69.
Weiner M, Peloquin C, Burman W, et al. Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. Antimicrob Agents Chemother. 2010;54:4192–200.
70.
Ramesh K, Hemanth Kumar AK, Kannan T, et al. SLCO1B1 gene polymorphisms do not influence plasma rifampicin concentrations in a south Indian population. Int J Tuberc Lung Dis. 2016;20:1231–5.
71.
Sloan DJ, McCallum AD, Schipani A, et al. Genetic determinants of the pharmacokinetic variability of rifampin in Malawian adults with pulmonary tuberculosis. Antimicrob Agents Chemother. 2017;61:pii:e00210–7.
72.
Kumar AKH, Chandrasekaran V, Kumar AK, et al. Food significantly reduces plasma concentrations of first-line anti-tuberculosis drugs. Indian J Med Res. 2017;145:530–5.
73.
Requena-Méndez A, Davies G, Waterhouse D, et al. Intra-individual effects of food upon the pharmacokinetics of rifampicin and isoniazid. J Antimicrob Chemother. 2019;74:416–24.
74.
Rockwood N, Pasipanodya JG, Denti P, et al. Concentration-dependent antagonism and culture conversion in pulmonary tuberculosis. Clin Infect Dis. 2017;64:1350–9.
75.
76.
Swaminathan S, Pasipanodya JG, Ramachandran G, et al. Drug concentration thresholds predictive of therapy failure and death in children with tuberculosis: bread crumb trails in random forests. Clin Infect Dis. 2016;63:S63–74.
77.
Guiastrennec B, Ramachandran G, Karlsson MO, et al. Suboptimal antituberculosis drug concentrations and outcomes in small and HIV-coinfected children in India: recommendations for dose modifications. Clin Pharmacol Ther. 2018;104:733–41.
Metadata
Title
Pharmacokinetics of First-Line Anti-Tubercular Drugs
Authors
Aparna Mukherjee
Rakesh Lodha
S. K. Kabra
Publication date
01-05-2019
Publisher
Springer India
Published in
Indian Journal of Pediatrics / Issue 5/2019
Print ISSN: 0019-5456
Electronic ISSN: 0973-7693
DOI
https://doi.org/10.1007/s12098-019-02911-w

Other articles of this Issue 5/2019

Indian Journal of Pediatrics 5/2019 Go to the issue

Editorial Commentary

The Significant Psychological Burden of a Celiac Family: Overlooked and Untreated

Scientific Letter

A Girl with Palpitations and Periodic Weakness

Commentary

Mitigating Painful Vaccination

Review Article

Newer Diagnostic Tests and their Application in Pediatric TB

Original Article

Liver Involvement in Congenital Hypopituitarism

Original Article

Respiratory Pathogens in Infants Diagnosed with Acute Lower Respiratory Tract Infection in a Tertiary Care Hospital of Western India Using Multiplex Real Time PCR